Cargando…
Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis
Advanced systemic mastocytosis (advSM) is characterized by the presence of an acquired KIT D816V mutation in >90% of patients. In the majority of patients, KIT D816V is not only detected in mast cells but also in other hematopoietic lineages. We sought to investigate the effects of the KIT-inhibi...
Autores principales: | Lübke, Johannes, Naumann, Nicole, Kluger, Sebastian, Schwaab, Juliana, Metzgeroth, Georgia, Evans, Erica, Gardino, Alexandra K., Lengauer, Christoph, Hofmann, Wolf-Karsten, Fabarius, Alice, Cross, Nicholas C. P., Reiter, Andreas, Jawhar, Mohamad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756065/ https://www.ncbi.nlm.nih.gov/pubmed/30911112 http://dx.doi.org/10.1038/s41375-019-0450-8 |
Ejemplares similares
-
P1036: REAL-WORLD EFFICACY AND SAFETY OF MIDOSTAURIN-TREATMENT IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS
por: Lübke, Johannes, et al.
Publicado: (2023) -
Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis
por: Naumann, Nicole, et al.
Publicado: (2021) -
CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V(+) Neoplastic Mast Cells
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2022) -
KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis
por: Jawhar, Mohamad, et al.
Publicado: (2019) -
An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis
por: Riffel, Philipp, et al.
Publicado: (2020)